|
US4045485A
(en)
|
1968-07-02 |
1977-08-30 |
Syntex Corporation |
Naphthyl acetaldehyde derivatives; methods of use thereof; and processes for the preparation thereof
|
|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
|
US5360811A
(en)
|
1990-03-13 |
1994-11-01 |
Hoechst-Roussel Pharmaceuticals Incorporated |
1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
|
|
JP3545461B2
(ja)
|
1993-09-10 |
2004-07-21 |
エーザイ株式会社 |
二環式ヘテロ環含有スルホンアミド誘導体
|
|
WO1996007655A1
(en)
|
1994-09-06 |
1996-03-14 |
Banyu Pharmaceutical Co., Ltd. |
Novel carbapenem derivative
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
CA2269561C
(en)
|
1998-04-22 |
2007-06-05 |
Dainippon Ink And Chemicals, Inc. |
Naphthalene derivative and liquid crystal composition comprising the same
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
IL131264A0
(en)
|
1999-08-05 |
2001-01-28 |
Yeda Res & Dev |
Photochromic naphthopyran compounds
|
|
EP1382339B1
(en)
|
1999-12-10 |
2007-12-05 |
Pfizer Products Inc. |
Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
|
|
DE10002509A1
(de)
|
2000-01-21 |
2001-07-26 |
Gruenenthal Gmbh |
Substituierte Glutarimide
|
|
ES2243461T3
(es)
|
2000-02-28 |
2005-12-01 |
Sugen, Inc. |
Compuestos de 3-(pirolillactona) -2-indolinona como inhibidores quinasa.
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US7041298B2
(en)
|
2000-09-08 |
2006-05-09 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
EP1389617B1
(en)
|
2001-04-27 |
2007-01-03 |
Zenyaku Kogyo Kabushiki Kaisha |
Heterocyclic compound and antitumor agent containing the same as active ingredient
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
WO2004019973A1
(en)
|
2002-08-14 |
2004-03-11 |
Atugen Ag |
Use of protein kinase n beta
|
|
KR20070087266A
(ko)
|
2003-04-03 |
2007-08-28 |
세마포르 파머슈티컬즈, 아이엔씨. |
피아이-3 키나아제 억제제 프로드러그
|
|
CN1832939B
(zh)
|
2003-05-30 |
2010-04-28 |
杰明X医药品加拿大公司 |
用于治疗癌症或病毒病的三杂环化合物、组合物和方法
|
|
US7173015B2
(en)
|
2003-07-03 |
2007-02-06 |
The Trustees Of The University Of Pennsylvania |
Inhibition of Syk kinase expression
|
|
JP4398263B2
(ja)
|
2004-01-13 |
2010-01-13 |
富士通株式会社 |
経路設計方法
|
|
SI2612862T1
(sl)
|
2004-05-13 |
2017-04-26 |
Icos Corporation |
Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
EP1888550B1
(en)
|
2005-05-12 |
2014-06-25 |
AbbVie Bahamas Ltd. |
Apoptosis promoters
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
BRPI0617162B8
(pt)
|
2005-10-07 |
2021-05-25 |
Exelixis Inc |
compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
|
|
CN103626742B
(zh)
|
2005-11-01 |
2017-04-26 |
塔格根公司 |
激酶的联-芳基间-嘧啶抑制剂
|
|
EP2455382B1
(en)
|
2005-12-13 |
2016-10-26 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
UA96283C2
(uk)
|
2005-12-23 |
2011-10-25 |
Зіланд Фарма А/С |
Модифіковані міметики лізину
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
MX2008013578A
(es)
|
2006-04-26 |
2009-03-23 |
Hoffmann La Roche |
Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
|
|
BRPI0622054B8
(pt)
|
2006-09-22 |
2021-05-25 |
Oxford Amherst Llc |
composto e composição farmacêutica
|
|
US20100279316A1
(en)
|
2007-01-19 |
2010-11-04 |
Leonid Gorelik |
Antibodies to Phosphorylated IRAK4
|
|
HRP20151386T1
(hr)
|
2007-03-12 |
2016-02-26 |
Ym Biosciences Australia Pty Ltd |
Fenil aminopirimidinski spojevi i njihova primjena
|
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
GB0706793D0
(en)
|
2007-04-05 |
2007-05-16 |
Evotec Ag |
Compounds
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
US8370032B2
(en)
|
2007-07-12 |
2013-02-05 |
Toyota Motor Engineering & Manufacturing North America, Inc. |
Systems and methods for shift control for vehicular transmission
|
|
ES2776406T3
(es)
|
2007-07-12 |
2020-07-30 |
Gitr Inc |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
EP2217716A4
(en)
|
2007-11-09 |
2011-02-09 |
Salk Inst For Biological Studi |
USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
|
|
JP5583592B2
(ja)
|
2007-11-30 |
2014-09-03 |
ニューリンク ジェネティクス コーポレイション |
Ｉｄｏ阻害剤
|
|
US8158616B2
(en)
|
2008-03-11 |
2012-04-17 |
Incyte Corporation |
Azetidine and cyclobutane derivatives as JAK inhibitors
|
|
JP2011518841A
(ja)
|
2008-04-24 |
2011-06-30 |
ニューリンク ジェネティクス， インコーポレイテッド |
Ｉｄｏ阻害剤
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
US8921037B2
(en)
|
2008-12-16 |
2014-12-30 |
Bo Han |
PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
|
|
EP2473531A4
(en)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
Anti-gitr antibodies
|
|
JP2012254939A
(ja)
|
2009-10-07 |
2012-12-27 |
Astellas Pharma Inc |
オキサゾール化合物
|
|
US8722720B2
(en)
|
2009-10-28 |
2014-05-13 |
Newlink Genetics Corporation |
Imidazole derivatives as IDO inhibitors
|
|
PH12012500881A1
(en)
|
2009-12-10 |
2017-07-26 |
Hoffmann La Roche |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
EP2536706B1
(en)
|
2010-02-11 |
2017-06-14 |
Celgene Corporation |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
JP5998060B2
(ja)
|
2010-03-04 |
2016-09-28 |
マクロジェニクス，インコーポレーテッド |
Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
|
|
CA2789076C
(en)
|
2010-03-05 |
2017-11-21 |
F. Hoffmann-La Roche Ag |
Antibodies against human colony stimulating factor-1 receptor and uses thereof
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
US8114621B2
(en)
|
2010-03-12 |
2012-02-14 |
Saladax Biomedical Inc. |
Lenalidomide and thalidomide immunoassays
|
|
MX378336B
(es)
|
2010-05-04 |
2025-03-10 |
Five Prime Therapeutics Inc |
Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
|
|
HRP20181598T1
(hr)
|
2010-06-03 |
2018-11-30 |
Abbvie Biotechnology Ltd |
Uporaba i pripravci za liječenje hidradenitis suppurativa (hs)
|
|
SG186389A1
(en)
|
2010-06-30 |
2013-01-30 |
Univ Brandeis |
Small-molecule-targeted protein degradation
|
|
JP5985473B2
(ja)
|
2010-07-13 |
2016-09-06 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
|
|
PT2614082T
(pt)
|
2010-09-09 |
2018-12-03 |
Pfizer |
Moléculas de ligação a 4-1bb
|
|
KR20180099933A
(ko)
|
2010-11-19 |
2018-09-05 |
리간드 파마슈티칼스 인코포레이티드 |
복소환 아민 및 이의 용도
|
|
AU2011338615B2
(en)
|
2010-12-07 |
2017-07-27 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
BR112013015460B1
(pt)
|
2010-12-20 |
2022-01-25 |
Merck Serono S.A. |
Derivados de indazolil triazol, kit, e composição farmacêutica
|
|
US8703941B2
(en)
|
2011-01-10 |
2014-04-22 |
Nimbus Iris, Inc. |
IRAK inhibitors and uses thereof
|
|
WO2012129258A1
(en)
|
2011-03-22 |
2012-09-27 |
Merck Sharp & Dohme Corp. |
Amidopyrazole inhibitors of interleukin receptor-associated kinases
|
|
NO2694640T3
(https=)
|
2011-04-15 |
2018-03-17 |
|
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
RU2606120C2
(ru)
|
2011-08-31 |
2017-01-10 |
Хантсман Эдванст Матириалз (Свитзеленд) Гмбх |
Способ пропитки реакторов с воздушным сердечником, подвергнутый пропитке реактор с воздушным сердечником и применение системы пропитки
|
|
WO2013042137A1
(en)
|
2011-09-19 |
2013-03-28 |
Aurigene Discovery Technologies Limited |
Bicyclic heterocycles as irak4 inhibitors
|
|
WO2013066729A1
(en)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
BR112014012624A2
(pt)
|
2011-12-15 |
2018-10-09 |
F Hoffmann-La Roche Ag |
anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
|
|
CN104582705A
(zh)
|
2012-01-10 |
2015-04-29 |
林伯士艾瑞斯公司 |
白介素-1受体相关激酶(irak)抑制剂和其用途
|
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
|
WO2013106614A1
(en)
|
2012-01-13 |
2013-07-18 |
Bristol-Myers Squibb Company |
Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
|
|
CN104254533B
(zh)
|
2012-01-13 |
2017-09-08 |
百时美施贵宝公司 |
用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
|
|
EP2802576B1
(en)
|
2012-01-13 |
2018-06-27 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
|
RU2014136332A
(ru)
|
2012-02-06 |
2016-03-27 |
Дженентек, Инк. |
Композиции и способы применения ингибиторов csf1r
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
EP2847220A1
(en)
|
2012-05-11 |
2015-03-18 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
SG11201500005SA
(en)
|
2012-07-10 |
2015-01-29 |
Ares Trading Sa |
Pyrimidine pyrazolyl derivatives
|
|
US20140018361A1
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
HK1210696A1
(en)
|
2012-07-11 |
2016-05-06 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2014011906A2
(en)
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
BR112015002285B1
(pt)
|
2012-08-09 |
2022-05-10 |
Celgene Corporation |
Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
US9422331B2
(en)
|
2012-09-19 |
2016-08-23 |
Hoffmann-La Roche Inc. |
2-oxo-2,3,4,5-tetrahydro-1 H-benzo[B]diazepines and their use in the treatment of cancer
|
|
WO2014058685A1
(en)
|
2012-10-08 |
2014-04-17 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
WO2014058691A1
(en)
|
2012-10-08 |
2014-04-17 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
KR20150079963A
(ko)
|
2012-11-08 |
2015-07-08 |
브리스톨-마이어스 스큅 컴퍼니 |
키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물
|
|
US9315494B2
(en)
|
2012-11-08 |
2016-04-19 |
Bristol-Myers Squibb Company |
Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
|
|
JP2016505012A
(ja)
*
|
2013-01-10 |
2016-02-18 |
ニンバス アイリス， インコーポレイテッド |
Ｉｒａｋ阻害剤およびその使用
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
LT2953952T
(lt)
|
2013-02-07 |
2017-08-25 |
Merck Patent Gmbh |
Makrocikliniai piridazinono dariniai
|
|
EP2953944B1
(en)
|
2013-02-07 |
2017-04-26 |
Merck Patent GmbH |
Pyridazinone-amides derivatives
|
|
EP2970334B1
(en)
|
2013-03-15 |
2018-05-23 |
Biogen MA Inc. |
Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
|
|
WO2014142237A1
(ja)
|
2013-03-15 |
2014-09-18 |
日本ゼオン株式会社 |
中空重合体粒子の水性分散液およびその製造方法
|
|
BR112016006319A2
(pt)
|
2013-09-27 |
2017-08-01 |
Nimbus Iris Inc |
inibidores de irak e usos dos mesmos
|
|
MX2021012208A
(es)
|
2013-10-04 |
2023-01-19 |
Infinity Pharmaceuticals Inc |
Compuestos heterocíclicos y usos de los mismos.
|
|
CN105899505B
(zh)
|
2013-11-08 |
2018-08-28 |
武田药品工业株式会社 |
用于治疗自身免疫病症的吡唑
|
|
CN104650092B
(zh)
*
|
2013-11-16 |
2017-11-10 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
|
JP6680683B2
(ja)
|
2013-11-18 |
2020-04-15 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
テトラヒドロ−ベンゾジアゼピノン類
|
|
JP6496731B2
(ja)
|
2013-11-27 |
2019-04-03 |
シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
TW201609693A
(zh)
|
2014-01-03 |
2016-03-16 |
必治妥美雅史谷比公司 |
雜芳基取代之菸鹼醯胺化合物
|
|
SG11201605408RA
(en)
|
2014-01-10 |
2016-07-28 |
Aurigene Discovery Tech Ltd |
Indazole compounds as irak4 inhibitors
|
|
FI3805233T3
(fi)
|
2014-01-13 |
2024-04-17 |
Aurigene Oncology Ltd |
N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon
|
|
RU2016137674A
(ru)
|
2014-03-17 |
2018-04-18 |
Ф. Хоффманн-Ля Рош Аг |
Производные пиперидиндиона
|
|
CN106255689B
(zh)
|
2014-03-19 |
2019-09-17 |
勃林格殷格翰国际有限公司 |
杂芳基syk抑制剂
|
|
MA39838B1
(fr)
|
2014-04-04 |
2019-05-31 |
Pfizer |
Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
|
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
AU2015247817C1
(en)
|
2014-04-14 |
2022-02-10 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
JP2017513954A
(ja)
|
2014-04-22 |
2017-06-01 |
ニンバス アイリス， インコーポレイテッド |
Ｉｒａｋ阻害剤およびその使用
|
|
JP2017518348A
(ja)
|
2014-06-20 |
2017-07-06 |
オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ |
Ｉｒａｋ４阻害剤としての置換インダゾール化合物
|
|
US9141124B1
(en)
|
2014-06-25 |
2015-09-22 |
Elite Semiconductor Memory Technology Inc. |
Bandgap reference circuit
|
|
WO2015200795A1
(en)
|
2014-06-27 |
2015-12-30 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
|
US10246456B2
(en)
|
2014-07-18 |
2019-04-02 |
Biogen Ma Inc. |
IRAK4 inhibiting agents
|
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
CN105461694B
(zh)
*
|
2014-09-27 |
2019-05-24 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
|
US9926330B2
(en)
|
2014-09-30 |
2018-03-27 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
EP3200790B1
(en)
|
2014-09-30 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
US9932350B2
(en)
|
2014-09-30 |
2018-04-03 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
US9969749B2
(en)
|
2014-09-30 |
2018-05-15 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
CA2964982C
(en)
|
2014-11-20 |
2022-07-05 |
Merck Patent Gmbh |
Heteroaryl compounds as irak inhibitors and uses thereof
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP3267996B1
(en)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
|
WO2016144848A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of irak4 activity
|
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
|
EP3268003B1
(en)
|
2015-03-12 |
2020-07-29 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
|
US10040798B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of IRAK4 activity
|
|
US10730870B2
(en)
|
2015-03-18 |
2020-08-04 |
Arvinas Operations, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
EA039043B1
(ru)
|
2015-04-22 |
2021-11-25 |
Райджел Фармасьютикалз, Инк. |
Пиразольные соединения и способ получения и применения данных соединений
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
UY36660A
(es)
|
2015-04-30 |
2016-11-30 |
Bayer Pharma AG |
Combinaciones de inhibidores de irak4
|
|
HUE054149T2
(hu)
|
2015-06-04 |
2021-08-30 |
Arvinas Operations Inc |
Proteolízis imid-alapú modulátorai és ezekkel kapcsolatos felhasználási eljárások
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
TW201718571A
(zh)
|
2015-06-24 |
2017-06-01 |
必治妥美雅史谷比公司 |
經雜芳基取代之胺基吡啶化合物
|
|
CN105085620B
(zh)
|
2015-06-25 |
2018-05-08 |
中山大学附属第一医院 |
一种靶向泛素化降解Smad3的化合物
|
|
WO2017004133A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
US9848583B2
(en)
|
2015-07-02 |
2017-12-26 |
Ellis Junior Smith |
Retractable leash
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017011371A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc |
Mdm2-based modulators of proteolysis and associated methods of use
|
|
CA2988436A1
(en)
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
US10669234B2
(en)
|
2015-07-14 |
2020-06-02 |
Mission Therapeutics Limited |
Cyanopyrrolidines as dub inhibitors for the treatment of cancer
|
|
BR112018000624A2
(pt)
|
2015-07-15 |
2018-09-18 |
Aurigene Discovery Technologies Limited |
compostos de indazol e azaindazol como inibidores de irak-4
|
|
JP2018524365A
(ja)
|
2015-07-15 |
2018-08-30 |
アウリジーン ディスカバリー テクノロジーズ リミテッド |
Ｉｒａｋ−４阻害剤としての置換アザ化合物
|
|
EP3337476A4
(en)
*
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
ES2865199T3
(es)
|
2015-08-27 |
2021-10-15 |
Pfizer |
Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
|
|
GB201516243D0
(en)
*
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CN108290879B
(zh)
|
2015-09-18 |
2022-01-11 |
默克专利有限公司 |
用作irak抑制剂的杂芳基化合物及其用途
|
|
KR102650026B1
(ko)
|
2015-09-18 |
2024-03-22 |
메르크 파텐트 게엠베하 |
Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도
|
|
BR112018006689A2
(pt)
|
2015-10-02 |
2018-10-09 |
Dana Farber Cancer Inst Inc |
terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle
|
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
|
AU2016349781A1
(en)
|
2015-11-02 |
2018-05-10 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
|
EP3383363B1
(en)
|
2015-11-30 |
2021-01-06 |
Anacor Pharmaceuticals, Inc. |
Topical pharmaceutical formulations for treating inflammatory-related conditions
|
|
WO2017108744A1
(de)
|
2015-12-22 |
2017-06-29 |
Bayer Pharma Aktiengesellschaft |
Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
|
EP3394066A2
(en)
|
2015-12-22 |
2018-10-31 |
H. Hoffnabb-La Roche Ag |
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
|
|
US20200216454A1
(en)
|
2015-12-30 |
2020-07-09 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for her3 degradation and methods of use
|
|
US20190016703A1
(en)
|
2015-12-30 |
2019-01-17 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
|
WO2017127430A1
(en)
|
2016-01-20 |
2017-07-27 |
Biogen Ma Inc. |
Irak4 inhibiting agents
|
|
EP3423446B1
(de)
|
2016-03-03 |
2020-09-16 |
Bayer Pharma Aktiengesellschaft |
Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
|
US11395820B2
(en)
|
2016-03-16 |
2022-07-26 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Small molecules against cereblon to enhance effector t cell function
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
AU2017246452C1
(en)
|
2016-04-06 |
2021-06-03 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
|
WO2017176958A1
(en)
|
2016-04-06 |
2017-10-12 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
CN109790143A
(zh)
*
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
|
WO2017207385A1
(de)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
|
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
WO2017223243A1
(en)
*
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
JP7065840B2
(ja)
|
2016-06-27 |
2022-05-12 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
２，４－ジアミノ－ピリミジン化合物ならびに該化合物の作製法および使用法
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
|
JP2019196309A
(ja)
|
2016-09-15 |
2019-11-14 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
WO2018071606A1
(en)
|
2016-10-11 |
2018-04-19 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
US10925868B2
(en)
|
2016-11-10 |
2021-02-23 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
|
CA3042731A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
|
|
MX2019007646A
(es)
*
|
2016-12-23 |
2019-09-06 |
Arvinas Operations Inc |
Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
|
|
CN108322937B
(zh)
|
2017-01-18 |
2020-08-11 |
上海诺基亚贝尔股份有限公司 |
无线接入网中用于网络切片的资源分配方法和编排器
|
|
AU2018211975B2
(en)
*
|
2017-01-26 |
2022-05-26 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
BR112019015484A2
(pt)
*
|
2017-01-31 |
2020-04-28 |
Arvinas Operations Inc |
ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
|
|
TW202340194A
(zh)
|
2017-02-16 |
2023-10-16 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
PE20191817A1
(es)
|
2017-05-11 |
2019-12-27 |
Bristol Myers Squibb Co |
Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
|
|
EP3630291B9
(en)
|
2017-05-26 |
2024-05-29 |
Cancer Research Technology Limited |
Benzimidazolone derived inhibitors of bcl6
|
|
WO2018226542A1
(en)
|
2017-06-09 |
2018-12-13 |
Arvinas, Inc. |
Modulators of proteolysis and associated methods of use
|
|
WO2018232288A1
(en)
|
2017-06-16 |
2018-12-20 |
Genentech, Inc. |
Diagnostic and therapeutic methods for irak4-mediated disorders and conditions
|
|
EP4717317A2
(en)
|
2017-06-20 |
2026-04-01 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
MX2020003190A
(es)
*
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
JP7311162B2
(ja)
|
2017-10-10 |
2023-07-19 |
アルデイラ セラピューティクス， インコーポレイテッド |
炎症性障害の処置
|
|
EP3700901A1
(en)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
|
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
|
WO2019094772A1
(en)
|
2017-11-10 |
2019-05-16 |
The Regents Of The University Of Michigan |
Ash1l degraders and methods of treatment therewith
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
CN109912655B
(zh)
|
2017-12-13 |
2021-12-10 |
上海科技大学 |
Alk蛋白降解剂及其抗肿瘤应用
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019160915A1
(en)
*
|
2018-02-14 |
2019-08-22 |
Dana-Farber Cancer Institute, Inc. |
Irak degraders and uses thereof
|
|
US11802132B2
(en)
|
2018-02-23 |
2023-10-31 |
Dana-Farber Cancer Institute, Inc. |
Small molecules for inducing selective protein degradation and uses thereof
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
US20220356185A1
(en)
|
2018-07-06 |
2022-11-10 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
CA3102996A1
(en)
|
2018-07-20 |
2020-01-23 |
Dana-Farber Cancer Institute, Inc. |
Degraders that target proteins via keap1
|
|
US12109193B2
(en)
|
2018-07-31 |
2024-10-08 |
Loxo Oncology Inc. |
Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
|
|
EP3841100A1
(en)
|
2018-08-20 |
2021-06-30 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
|
MX2021001957A
(es)
|
2018-08-22 |
2021-07-15 |
Cullgen Shanghai Inc |
Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
|
|
CN110862375B
(zh)
|
2018-08-27 |
2022-10-25 |
深圳铂立健医药有限公司 |
吡唑化合物及其药物组合物和应用
|
|
JP7712867B2
(ja)
|
2018-11-02 |
2025-07-24 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
アセチル化ライター阻害剤の開発およびその使用
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
WO2020150626A1
(en)
|
2019-01-18 |
2020-07-23 |
Biogen Ma Inc. |
Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
|
|
TWI875749B
(zh)
|
2019-04-05 |
2025-03-11 |
美商凱麥拉醫療公司 |
Stat降解劑及其用途
|
|
US20220324880A1
(en)
|
2019-06-10 |
2022-10-13 |
Kymara Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
US20230072658A1
(en)
|
2019-06-10 |
2023-03-09 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020251969A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
WO2020264490A1
(en)
|
2019-06-28 |
2020-12-30 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US20230303526A1
(en)
|
2019-06-28 |
2023-09-28 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021011634A1
(en)
|
2019-07-15 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US20220281831A1
(en)
|
2019-07-15 |
2022-09-08 |
Kymera Therapeutics, Inc. |
Fused-glutarimide crbn ligands and uses thereof
|
|
WO2021011871A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021018118A1
(en)
|
2019-07-29 |
2021-02-04 |
Janssen Pharmaceutica Nv |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 1 proteins
|
|
JP2022548095A
(ja)
|
2019-09-16 |
2022-11-16 |
ノバルティス アーゲー |
接着分解剤及びその使用方法
|
|
US12551564B2
(en)
|
2019-12-10 |
2026-02-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
US20230219945A1
(en)
|
2019-12-17 |
2023-07-13 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US20230122219A1
(en)
|
2020-02-03 |
2023-04-20 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021222366A1
(en)
|
2020-04-28 |
2021-11-04 |
Kymera Therapeutics, Inc. |
Irak inhibitors and uses thereof
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
WO2021247897A1
(en)
|
2020-06-03 |
2021-12-09 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
MX2022016061A
(es)
|
2020-06-17 |
2023-02-02 |
Kymera Therapeutics Inc |
Degradadores de cinasa asociada al receptor interleucina-1 (irak) y usos de los mismos.
|
|
US11857535B2
(en)
|
2020-07-30 |
2024-01-02 |
Kymera Therapeutics, Inc. |
Methods of treating mutant lymphomas
|
|
TWI833104B
(zh)
|
2020-08-05 |
2024-02-21 |
大陸商上海領泰生物醫藥科技有限公司 |
靶向蛋白降解化合物及其製備方法和應用
|
|
EP4232059A4
(en)
|
2020-10-21 |
2024-09-11 |
Kymera Therapeutics, Inc. |
DOUBLE DEGRADERS AND USES THEREOF
|
|
CA3200608A1
(en)
|
2020-12-09 |
2022-06-16 |
Xiaozhang Zheng |
Irak degraders and uses thereof
|
|
PH12023500015A1
(en)
|
2020-12-30 |
2024-03-11 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
US20240383887A1
(en)
|
2021-05-07 |
2024-11-21 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
US12187744B2
(en)
|
2021-10-29 |
2025-01-07 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and synthesis thereof
|
|
WO2023137439A1
(en)
|
2022-01-14 |
2023-07-20 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
EP4499068A4
(en)
|
2022-03-31 |
2026-03-25 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
JP2025534698A
(ja)
|
2022-10-13 |
2025-10-17 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４デグレーダーの塩の形態
|
|
IL321211A
(en)
|
2022-12-13 |
2025-07-01 |
Kymera Therapeutics Inc |
IRAK4 joints and their uses
|